2013). However, potential cardiovascular effects may discourage its prescription for hair loss by dermatologists. This case series details the tolerability and adherence rates of oral minoxidil for treatment of AGA or TA.
Using the electronic medical records (EMR; YES EMR, Toronto, Canada) of two dermatology clinics, patients with AGA or TA who were prescribed oral minoxidil from December 2016 through January 2018 were identified. These patients were diagnosed clinically by the author (RAB). They had previously used topical minoxidil and were seeking alternate treatment. Accordingly, they were prescribed oral minoxidil 1.25 mg nightly. This dose was determined in 2016 after reviewing reports of successful hair growth with 1 mg dosing (Sinclair, 2016; Yang & Thai, 2015) , and based on the availability of a 2.5 mg tablet in Canada, which was halved. All patients were informed about the drug's indication and side-effect profile (Pfizer Canada, 2013) .
Patients with prior hypotension, cardiac comorbidities, or lack of prescription contraception were not prescribed the medication.
Clinic notes were assessed for prescription compliance, reports of side-effects, and other unique details. All patients prescribed minoxidil, regardless of their adherence to the prescription, were included in this as-treated analysis.
The search identified a total of 20 patients (18 women and two men, average age 41 years old) who were prescribed oral minoxidil (Table 1) . Patients with a primary diagnosis of AGA (16 patients; 80%) or TA (four patients; 20%) were prescribed an initial 3-month course. Eighteen out of 20 patients filled their prescription for oral minoxidil (90%); two were discouraged by prescription warnings.
The medication was continued by 14/18 (78%) patients at reassessment. Patients who discontinued oral minoxidil cited aversion to pills (2), forgetfulness (1), and headache with stress of a new job (1).
The average duration of prescription use across all 18 patients was 6 months.
Blood pressure monitoring was requested of all patients. Among 9 patients who monitored their blood pressure, it either remained within normal range (7 patients) or improved from hypertensive levels (two patients). One patient (6%) reported hypotensive symptoms and urticaria for 8-10 days. No patients experienced significant cardiac morbidity.
Six of 18 patients (33%) reported decreased hair shedding, while five patients (28%) reported increased scalp hair (5/18). Hypertrichosis was reported in 39% (7/18) on the face (most commonly the skin lip) and arms, yet all affected patients continued therapy due to its perceived benefit for their scalp hair. 
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